• 1
    Ring J. Allergy in Practice. Berlin Heidelberg New York: Springer, 2005.
  • 2
    Bousquet J, Lockey R, Malling H-J, the WHO panel members. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol 1998;102:558562.
  • 3
    de Weck AL, Ring J. CIA, Collegium Internationale Allergologicum: History and Aims of a Special International Community Devoted to Allergy Research, 1954–1996, 2nd edn. Munich: Urban Vogel, 2006.
  • 4
    Noon L. Prophylactic inoculations against hay fever. Lancet 1911;1:15721573.
  • 5
    Simons FER (ed.). Ancestors of allergy. Global Medical Communications, New York, 1994, pp. 114117.
  • 6
    Cooke RA. Studies in Specific Hypersensitiveness: IX. On the Phenomenon of Hyposensitization (the Clinically Lessened Sensitiveness of Allergy). J Immunol 1922;7:219242.
  • 7
    Pichler WJ. Specific and nonspecific (anti-IgE) immunotherapy of allergic diseases. Ther Umsch 2001;58:329336.
  • 8
    Schadewaldt H. Geschichte der Allergie, Band 1–4. 1 ed. Muenchen-Deisenhofen: Dustri-Verlag, 19791983.
  • 9
    Jenner E. An inquiry into the causes and effects of the variolae vaccinae. A disease discovered in some of the western counties of England, particularly Gloucestershire, and known by the name of the cow pox. Low, London, 1798.
  • 10
    Giel S. Die Schutpockenimpfung in Bayern, vom Anbeginn ihrer Entstehung und gesetzlichen Einführung bis auf gegenwärtige Zeit, dann mit besonderer Beachtung derselben in anderen Staaten. Bibliotheca Regia Monacensis, Munich, 1830, p. 105.
  • 11
    Hahnemann S. Die chronischen Krankheiten, ihre eigentümliche Natur und ihre homöopathische Heilung Arnoldische Buchhandlung, Dresden und Leipzig 1828.
  • 12
    Pipet A, Botturi K, Pinot D, Vervloet D, Magnan A. Allergen-specific immunotherapy in allergic rhinitis and asthma. Mechanisms and proof of efficacy. Respir Med 2009;103:800812.
  • 13
    Calderon MA, Alves B, Jacobson M, Hurwitz B, Sheikh A, Durham S. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev 2007;1:CD001936.
  • 14
    Wilson DR, Lima MT, Durham SR. Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis. Allergy 2005;60:412.
  • 15
    Bousquet J, Dahl R, Khaltaev N. Global alliance against chronic respiratory diseases. Allergy 2007;62:216223.
  • 16
    Dunbar WP. Zur Ursache und spec. Heil. des Heufiebers. Dtsch Med Wochenschr 1903;9:2428.
  • 17
    Dunbar WP. Zur Frage betreffend der Ätiologie und specifischen Heilung des Heufiebers. Berl Klin Wochenschrift 1903;40:569.
  • 18
    Wolff-Eisner A. Das Heufieber: sein Wesen und seine Behandlung. München: Lehmann, 1906.
  • 19
    Besredka A. Comment empecher l`anaphylaxie? C R Soc Biol 1907;59:1053.
  • 20
    Besredka A. Du mecanisme de l’anaphylaxie vis-a-visde serum de cheval C R Soc Biol 1907;59:294296.
  • 21
    Stead RH, Tomioka M, Quinonez G, Simon GT, Felten SY, Bienenstock J. Intestinal mucosal mast cells in normal and nematode-infected rat intestines are in intimate contact with peptidergic nerves. Proc Natl Acad Sci USA 1987;84:29752979.
  • 22
    Curtis HH. The immunizing cure of hay fever. NY Med J 1900;77:1618.
  • 23
    Rosenau MJ, Anderson JF. A new toxic Action of Horse Serum. J Med Res 1906;15:179208.
  • 24
    Pirquet Cv, Schick B. Die Serumkrankheit. Leipzig-Wien 1905.
  • 25
    Scheppegrell W. The Immunizing Treatment of Hay Fever. NY Med J 1909;90:1099.
  • 26
    Freeman J. Further observations on the treatment of hay fever by hypodermic inoculations of pollen vaccine. Lancet 1911;178:814817.
  • 27
    Cooke RA. The treatment of hay fever by active immunization. Laryngoscope 1914;25:108112.
  • 28
    Pasteur Vallery-Radot P, Blamoutier P. La cutièreaction dans l’asthme, la coryza spasmodique, le rhume de foins, la migraine, l’urticaire et l’èczèma. Presse Mèd 1925;33:385.
  • 29
    Lambert A, Bouin P, Ancel AP. Sur la skeptophylaxis. CR Soc Biol 1911;71:350.
  • 30
    Fell N, Rodney G, Marshall DE. Histamine-protein complexes: synthesis and immunologic investigation: I. histamine-azoprotein. J Immunol 1943;47:237249.
  • 31
    Cohen MB, Friedman HJ. Antibodies to histamine induced in human beings by histamine conjugates. J Allergy 1943;14:195202.
  • 32
    Sato Y, Roman M, Tighe H, Lee D, Corr M, Minh-Duc N et al. Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science 1996;273:352354.
  • 33
    Jutel M, Akdis M, Blaser K, Akdis CA. Mechanisms of allergen specific immunotherapy--T-cell tolerance and more. Allergy 2006;61:796807.
  • 34
    Jutel M, Akdis M, Budak F, Aebischer-Casaulta C, Wrzyszcz M, Blaser K et al. IL-10 and TGF-beta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur J Immunol 2003;33:12051214.
  • 35
    Frankland AW. High and low dosage pollen extract treatment in summer hay fever and asthma. Acta Allergol 1955;9:183187.
  • 36
    Norman PS, Lichtenstein LM, Marsh DG. Studies on allergoids from naturally occurring allergens. IV. Efficacy and safety of long-term allergoid treatment of ragweed hay fever. J Allergy Clin Immunol 1981;68:460470.
  • 37
    Marsh DG, Norman PS, Roebber M, Lichtenstein LM. Studies on allergoids from naturally occurring allergens. III. Preparation of ragweed pollen allergoids by aldehyde modification in two steps. J Allergy Clin Immunol 1981;68:449459.
  • 38
    Johansson SGO, Deuschl H, Zetterstrom O. Use of glutaraldehyde-modified timothy grass pollen extract in nasal hyposensitisation treatment of hay fever. Int Arch Allergy Appl Immunol 1979;60:447460.
  • 39
    Foucard T, Johansson SGO. Immunological studies in vitro and in vivo of children with pollenosis given immunotherapy with an aqueous and a glutaraldehyde-treated tyrosine-absorbed grass pollen extract. Clin Allergy 1976;6:429439.
  • 40
    Johansson SGO, Miller AC, Mullan N, Overell BG, Tees EC, Wheeler A. Glutaraldehyde-pollen-tyrosine: clinical and immunological studies. Clin Allergy 1974;4:255263.
  • 41
    Mösges R, Ritter B, Kayoko G, Allekotte S. Carbamylated monomeric allergoids as a therapeutic option for sublingual immunotherapy of dust mite- and grass pollen-induced allergic rhinoconjunctivitis: a systematic review of published trials with a meta-analysis of treatment using Lais tablets. Acta Dermatovenerol Alp Panonica Adriat 2010;19:310.
  • 42
    Johnson AG, Tomai M, Solem L, Beck L, Ribi E. Characterization of a nontoxic mono phosphoryl lipid. Rev Infect Dis 1987;9:512516.
  • 43
    Patel P, Salapatek A. Pollinex Quattro: a novel and well-tolerated, ultra short-course allergy vaccine. Expert Rev Vaccines 2006;5:617629.
  • 44
    Puggioni F, Durham SR, Francis JN. Monophosphoryl lipid A (MPL) promotes allergeninduced immune deviation in favour of Th1 responses. Allergy 2006;60:678684.
  • 45
    Lee WY, Sehon AH. Abrogation of reaginic antibodies with modified allergens. Nature 1977;267:618619.
  • 46
    Tulic MK, Fiset PO, Christodoulopoulos P, Vaillancourt P, Desrosiers M, Lavigne F et al. Amb a 1-immunostimulatory oligodeoxynucleotide conjugate immunotherapy decreases the nasal inflammatory response. J Allergy Clin Immunol 2004;113:235241.
  • 47
    Creticos PS, Schroeder JT, Hamilton RG, Balcer-Whaley SL, Khattignavong AP, Lindblad R et al. Immunotherapy with a ragweed-Toll-like receptor 9 agonist vaccine for allergic rhinitis N Engl J Med 2006;355:14451455.
  • 48
    Benson RL, Semenov H. Allergy in its relation to bee sting. J Allergy 1930;1:105.
  • 49
    Loveless MH, Cann JR. Distribution of allergic and blocking activity in human serum proteins fractionated by electrophoresis convection. Science 1953;117:105108.
  • 50
    Hahn G, Ostermayer H. Ueber das Bienengift. Berichte der Deutschen Chemischen Gesellschaft 1936;11:2407.
  • 51
    Lotter G. Sensibilisierung für Bienengift durch Typhus-Antitoxin und Desensibilisierung mit Forapin. Münch Med Wochenschr 1939;83:330331.
  • 52
    Hunt KJ, Valentine MD, Sobotka AK, Benton AW, Amodio FJ, Lichtenstein LM. A controlled trial of immunotherapy in insect hypersensitivity. N Engl J Med 1978;299:157161.
  • 53
    Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008;63(Suppl 86):8160.
  • 54
    Compalati E, Canonica GW, Passalacqua G, Baena-Cagnani CE. Considerations about the evaluation of the SLIT meta-analyses. J Allergy Clin Immunol 2010;125:509; author reply 509-10.
  • 55
    Durham SR, Emminger W, Kapp A, Colombo G, de Monchy JG, Rak S et al. Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet. J Allergy Clin Immunol 2010;125:131-8 e1-7.
  • 56
    Senti G, Prinz Vavricka BM, Erdmann I, Diaz MI, Markus R, McCormack SJ et al. Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial. Proc Natl Acad Sci USA 2008;105:1790817912.
  • 57
    Tovey ER, Johnson MC, Roche AL, Cobon GS, Baldo BA. Cloning and sequencing of a cDNA expressing a recombinant house dust mite protein that binds human IgE and corresponds to an important low molecular weight allergen. J Exp Med 1989;170:14571462.
  • 58
    Breiteneder H, Pettenburger K, Bito A, Valenta R, Kraft D, Rumpold H et al. The gene coding for the major birch pollen allergen Betv1, is highly homologous to a pea disease resistance response gene. EMBO J 1989;8:19351938.
  • 59
    Müller U, Akdis CA, Fricker M, Akdis M, Blesken T, Bettens F et al. Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom. J Allergy Clin Immunol 1998;101:747754.
  • 60
    Akdis M, Akdis C. Therapeutic manipulation of immune tolerance in allergic disease. Nat Rev Drug Discov 2009;8:645660.
  • 61
    Valenta R, Ferreira F, Focke-Tejkl M, Linhart B, Niederberger V, Swoboda I et al. From allergen genes to allergy vaccines. Annu Rev Immunol 2010;28:211241.
  • 62
    Bohle B, Breitwieser A, Zwolfer B, Jahn-Schmid B, Sara M, Sleytr UB et al. A novel approach to specific allergy treatment: the recombinant fusion protein of a bacterial cell surface (S-layer) protein and the major birch pollen allergen Bet v 1 (rSbsC-Bet v 1) combines reduced allergenicity with immunomodulating capacity. J Immunol 2004;172:66426648.
  • 63
    Akdis CA, Kussebi F, Pulendran B, Akdis M, Lauener R, Schmidt-Weber CB et al. Inhibition of T helper 2-type responses, IgE production and eosinophilia by synthetic lipopeptides. Eur J Immunol 2003;33:27172726.
  • 64
    Grange JM, Bottasso O, Stanford CA, Stanford JL. The use of mycobacterial adjuvant-based agents for immunotherapy of cancer. Vaccine 2008;26:49844990.
  • 65
    Zuany-Amorim C, Manlius C, Trifilieff A, Brunet LR, Rook G, Bowen G et al. Long-term protective and antigen-specific effect of heat-killed Mycobacterium vaccae in a murine model of allergic pulmonary inflammation. J Immunol 2002;169:14921499.
  • 66
    Kündig TM, Senti G, Schnetzler G, Wolf C, Prinz Vavricka BM, Fulurija A et al. Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults. J Allergy Clin Immunol 2006;117:14701476.
  • 67
    Nelson HS, Busse WW, Israel E, Baker JW, Charous BL, Kim KT et al. Daclizumab improves asthma control in patients with refractory asthma. J Allergy Clin Immunol 2005;115:134.
  • 68
    Morjaria JB, Chauhan HJ, Babu KS, Polosa R, Davies DE, Holgate ST. The role of a soluble TNFalpha receptor fusion protein (etanercept) in corticosteroid refractory asthma: a double blind, randomised, placebo controlled trial. Thorax 2008;63:584591.
  • 69
    Flood-Page P, Menzies-Gow A, Phipps S, Ying S, Wangoo A, Ludwig MS et al. Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J Clin Invest 2003;112:10291036.
  • 70
    Borish LC, Nelson HS, Lanz MJ, Claussen L, Whitmore JB, Agosti JM et al. Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebocontrolled trial. Am J Respir Crit Care Med 1999;160:18161823.
  • 71
    Gutermuth J, Bewersdorff M, Traidl-Hoffmann C, Ring J, Mueller MJ, Behrendt H et al. Immunomodulatory effects of aqueous birch pollen extracts and phytoprostanes on primary immune responses in vivo. J Allergy Clin Immunol 2007;120:293299.
  • 72
    Traidl-Hoffmann C, Mariani V, Hochrein H, Karg K, Wagner H, Ring J et al. Pollen-associated phytoprostanes inhibit dendritic cell interleukin-12 production and augment T helper type 2 cell polarization. J Exp Med 2005;201:627636.
  • 73
    Focke M, Marth K, Flicker S, Valenta R. Heterogeneity of commercial timothy grass pollen extracts. Clin Exp Allergy 2008;38:14001408.
  • 74
    Linhart B, Mothes-Luksch N, Vrtala S, Kneidinger M, Valent P, Valenta R. A hypoallergenic hybrid molecule with increased immunogenicity consisting of derivatives of the major grass pollen allergens, Phl p 2 and Phl p 6. Biol Chem 2008;389:925933.
  • 75
    Jutel M, Jaeger L, Suck R, Meyer H, Fiebig H, Cromwell O. Allergen-specific immunotherapy with recombinant grass pollen allergens. J Allergy Clin Immunol 2005;116:608613.
  • 76
    Pauli G, Larsen TH, Rak S, Horak F, Pastorello E, Valenta R et al. Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis. J Allergy Clin Immunol 2008;122:951960.
  • 77
    Valenta R, Niederberger V. Recombinant allergens for immunotherapy. J Allergy Clin Immunol 2007;119:826830.
  • 78
    Haselden BM, Kay AB, Larché M. Immunoglobulin E-independent major histocompatibility complex-restricted T cell peptide epitope-induced late asthmatic reactions. J Exp Med 1999;189:18851894.
  • 79
    Norman PS, Ohman JL Jr, Long AA, Creticos PS, Gefter MA, Shaked Z et al. Treatment of cat allergy with T-cell reactive peptides. Am J Respir Crit Care Med 1996;154:16231628.
  • 80
    Verhoef A, Alexander C, Kay AB, Larche M. T cell epitope immunotherapy induces a CD4+ T cell population with regulatory activity. PLoS Med 2005;2:e78.
  • 81
    Oldfield WL, Larche M, Kay AB. Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trial. Lancet 2002;360:4753.
  • 82
    Haselden BM, Larche M, Meng Q, Shirley K, Dworski R, Kaplan AP et al. Late asthmatic reactions provoked by intradermal injection of T-cell peptide epitopes are not associated with bronchial mucosal infiltration of eosinophils or T(H)2-type cells or with elevated concentrations of histamine or eicosanoids in bronchoalveolar fluid. J Allergy Clin Immunol 2001;108:394401.
  • 83
    Linhart B, Hartl A, Jahn-Schmid B, Verdino P, Keller W, Krauth MT et al. A hybrid molecule resembling the epitope spectrum of grass pollen for allergy vaccination. J Allergy Clin Immunol 2005;115:10101016.
  • 84
    Linhart B, Bigenzahn S, Hartl A, Lupinek C, Thalhamer J, Valenta R et al. Costimulation blockade inhibits allergic sensitization but does not affect established allergy in a murine model of grass pollen allergy. J Immunol 2007;178:39243931.
  • 85
    Valenta R. The future of antigen-specific immunotherapy of allergy. Nat Rev Immunol 2002;2:446453.
  • 86
    Kahlert H, Suck R, Weber B, Nandy A, Wald M, Keller W et al. Characterization of a hypoallergenic recombinant Bet v 1 variant as a candidate for allergen-specific immunotherapy. Int Arch Allergy Immunol 2008;145:193206.
  • 87
    Niederberger V, Horak F, Vrtala S, Spitzauer S, Krauth MT, Valent P et al. Vaccination with genetically engineered allergens prevents progression of allergic disease. Proc Natl Acad Sci USA 2004;101(Suppl 2):1467714682.
  • 88
    Vrtala S, Focke-Tejkl M, Swoboda I, Kraft D, Valenta R. Strategies for converting allergens into hypoallergenic vaccine candidates. Methods 2004;32:313320.
  • 89
    Rak S. Clinical results with a hypoallergenic recombinant birch pollen allergen derivative. Presented at 27th Congr., EAACI 2009, Warsaw, June 6–10 2009.
  • 90
    King TP, Jim SY, Monsalve RI, Kagey-Sobotka A, Lichtenstein LM, Spangfort MD. Recombinant allergens with reduced allergenicity but retaining immunogenicity of the natural allergens: hybrids of yellow jacket and paper wasp venom allergen antigen 5s. J Immunol 2001;166:60576065.
  • 91
    Casale TB, Busse WW, Kline JN, Ballas ZK, Moss MH, Townley RG et al. Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol 2006;117:134140.
  • 92
    Klunker S, Saggar LR, Seyfert-Margolis V, Asare AL, Casale TB, Durham SR et al. Combination treatment with omalizumab and rush immunotherapy for ragweedinduced allergic rhinitis: Inhibition of IgE-facilitated allergen binding. J Allergy Clin Immunol 2007;120:688695.
  • 93
    Ball T, Vrtala S, Sperr WR, Valent P, Susani M, Kraft D et al. Isolation of an immunodominant IgE hapten from an epitope expression cDNA library. Dissection of the allergic effector reaction. J Biol Chem 1994;269:2832328328.
  • 94
    Segal DM, Taurog JD, Metzger H. Dimeric immunoglobulin E serves as a unit signal for mast cell degranulation. Proc Natl Acad Sci USA 1977;74:29932997.
  • 95
    Ganglberger E, Sponer B, Schöll I, Wiedermann U, Baumann S, Hafner C et al. Monovalent fusion proteins of IgE mimotopes are safe for therapy of type I allergy. FASEB J 2001;15:25242526.
  • 96
    Suphioglu C, Schäppi G, Kenrick J, Levy D, Davies JM, O’Hehir R. A novel grass pollen allergen mimotope identified by phage display peptide library inhibits allergen-human IgE antibody interaction. FEBS Lett 2001;502:4652.
  • 97
    Bauer R, Scheiblhofer S, Kern K, Gruber C, Stepanoska T, Thalhamer T et al. Generation of hypoallergenic DNA vaccines by forced ubiquitination: preventive and therapeutic effects in a mouse model of allergy. J Allergy Clin Immunol 2006;118:269276.
  • 98
    Hochreiter R, Stepanoska T, Ferreira F, Valenta R, Vrtala S, Thalhamer J et al. Prevention of allergen-specific IgE production and suppression of an established Th2-type response by immunization with DNA encoding hypoallergenic allergen derivatives of Bet v 1, the major birch-pollen allergen. Eur J Immunol 2003;33:16671676.
  • 99
    Steptoe RJ, Ritchie JM, Harrison LC. Transfer of hematopoietic stem cells encoding autoantigen prevents autoimmune diabetes. J Clin Invest 2003;111:13571363.
  • 100
    Baranyi U, Linhart B, Pilat N, Gattringer M, Bagley J, Muehlbacher F et al. Tolerization of a type I allergic immune response through transplantation of genetically modified hematopoietic stem cells. J Immunol 2008;180:81688175.